Copyright
©The Author(s) 2015.
World J Gastroenterol. Jun 21, 2015; 21(23): 7281-7288
Published online Jun 21, 2015. doi: 10.3748/wjg.v21.i23.7281
Published online Jun 21, 2015. doi: 10.3748/wjg.v21.i23.7281
Characteristic | n (%)1 |
Total recruitment | 205 (100) |
ITT population | 197 (96.1) |
Age (yr) | |
Median (range) | 63 (34-80) |
mean ± SD | 62.3 ± 9.9 |
Gender | |
Males | 111 (56.4) |
Females | 86 (43.6) |
ECOG-PS | |
0 | 159 (80.7) |
1 | 38 (19.3) |
> 1 | 0 (0) |
Site of primary tumor | |
Colon (any region) | 141 (71.6) |
Rectum | 46 (23.4) |
Rectum + colon (any region) | 8 (4.1) |
Unknown | 2 (1.0) |
Prior treatments (adjuvant or neo-adjuvant) | |
Chemotherapy | 49 (24.9) |
Radiotherapy | 21 (10.7) |
None | 148 (75.1) |
N of metastases for each patient | |
1 | 105 (53.3) |
2 | 72 (36.5) |
> 3 | 20 (10.2) |
Site of metastases | |
Liver | 150 (76.1) |
Lung | 70 (35.5) |
Lymph nodes | 27 (13.7) |
Peritoneum | 14 (7.1) |
Other | 98 (48) |
Stage at first diagnosis | |
Local regional | 75 (38.1) |
Metastatic | 122 (61.9) |
KRAS and BRAF mutation status (34 evaluated) | |
Wild Type (KRAS/BRAF) | 18 (52.9) |
Mutated KRAS | 13 (38.2) |
Mutated BRAF | 2 (5.9) |
Mutated KRAS and BRAF | 1 (2.9) |
n (%)1 | |
CR (best overall response) | 10 (5.1) |
PR | 87 (44.2) |
SD | 55 (27.9) |
CB (CR + PR + SD) | 152 (77.1) |
PD | 13 (6.6) |
No tumor assessment | 32 (16.2) |
Reason for surgery | Residual disease | n (%)1 |
Curative | ||
No (radical surgery) | 26 (55.8) | |
Yes | 7 (13.5) | |
Unknown | 2 (3.9) | |
Not applicable | 4 (7.7) | |
Palliative | ||
No (radical surgery) | 2 (3.9) | |
Yes | 4 (7.7) | |
Unknown | 2 (3.9) | |
Not applicable | 1 (1.9) | |
Biopsy | ||
Yes | 1 (1.9) | |
Not applicable | 1 (1.9) | |
Unknown | ||
Unknown | 1 (1.9) | |
Not applicable | 2 (3.9) | |
Other | ||
Yes | 1 (1.9) | |
Not applicable | 2 (3.9) |
- Citation: Antonuzzo L, Giommoni E, Pastorelli D, Latiano T, Pavese I, Azzarello D, Aieta M, Pastina I, Di Fabio F, Bertolini A, Corsi DC, Mogavero S, Angelini V, Pazzagli M, Di Costanzo F. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. World J Gastroenterol 2015; 21(23): 7281-7288
- URL: https://www.wjgnet.com/1007-9327/full/v21/i23/7281.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i23.7281